<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937871</url>
  </required_header>
  <id_info>
    <org_study_id>14393</org_study_id>
    <secondary_id>H6D-MC-LVJE</secondary_id>
    <nct_id>NCT01937871</nct_id>
  </id_info>
  <brief_title>A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once-Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia and Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether tadalafil can reduce the signs and symptoms in
      men with Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia-Lower Urinary Tract
      Symptoms (BPH-LUTS) and improve their quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question was scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM).The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline Erectile dysfunction (ED) severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment.The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>IIEF is a 15 item self-reported questionnaire to assess overall erectile function and satisfaction during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0(low/no erectile function) to 5(high erectile function) and Question 15 is scored 1(very low confidence) to 5(very high confidence) with a total score ranging from 1 to 30.Higher scores represent better erectile function.LS mean of change from baseline to endpoint is from MMRM.The model includes effects for treatment,country/region,baseline lower urinary tract symptoms(LUTS) severity (moderate/severe),visit,treatment-by-visit interaction,centered baseline value(defined as the baseline value for a participant-the overall baseline mean value), placebo lead-in total IPSS change(change from Visit 2 at Visit 3),centered baseline-by-treatment and treatment-by-country/region interactions.The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Yes Responses to Question 2 of the Sexual Encounter Profile (SEP) Questionnaire at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Participant-assessed diary assesses the mean change from baseline in the percentage of &quot;yes&quot; responses to SEP Q2, &quot;Were you able to insert your penis into your partner's vagina?&quot;. The SEP Q2 score was determined as the percentage of &quot;yes&quot; responses to SEP Q2 out of all sexual attempts recorded during the time period. Change is defined as the percentage of &quot;yes&quot; responses at endpoint minus the percentage of &quot;yes&quot; responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p &gt;= 0.10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Participant-assessed diary assesses the mean change from baseline in the percentage of &quot;yes&quot; responses to SEP Q3, &quot;Did your erection last long enough for you to have successful intercourse?&quot;.The SEP Q3 score is determined as the percentage of &quot;yes&quot; responses to SEP Q3 out of all sexual attempts recorded during the time period. Change was defined as the percentage of &quot;yes&quot; responses at endpoint minus percentage of &quot;yes&quot; responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p &gt;= 0.10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IPSS at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question is scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM).The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline Erectile dysfunction (ED) severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Uroflowmetry Measures at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Qmax is defined as the peak urine flow rate (measured in milliliters per second [mL/sec] using standard calibrated flowmeter).
At each visit, a uroflowmetry assessment was considered valid and the data were included only if the prevoid total bladder volume (assessed by ultrasound) was &gt;=150 to &lt;=550 milliliters (mL) and the voided volume (Vcomp) was &gt;=125 mL. Changes in Qmax from baseline to endpoint in the double-blind treatment period were analyzed using Type III sums of squares ANOVA on rank-transformed data with a term for treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postvoid Residual Volume (PVR) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The amount of urine remaining in the bladder after void completion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IPSS Storage (Irritative) Subscore at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>IPSS Storage (Irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores ranged from 0 (no irritative symptoms) to 5 (frequent irritative symptoms), with total subscore of the 3 questions for irritative subscore ranging from 0 to 15; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline ED severity (mild/moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IPSS Voiding (Obstructive) Subscore at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>IPSS voiding (obstructive) subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores ranged from 0 (no obstructive symptoms) to 5 (frequent obstructive symptoms), with total subscore of the 4 questions of the obstructive score ranging from 0 to 20; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline ED severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IPSS Quality of Life (QoL) Index at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>IPSS QoL assess participant response to the following question:&quot;If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?&quot;. Response options are Delighted(0),Pleased(1);Mostly satisfied(2);mixed about equally satisfied and dissatisfied(3);Mostly dissatisfied(4);Unhappy(5);Terrible(6),with a total ranging from 0 to 6; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares(LS) mean of change from baseline(bl) to endpoint is from MMRM.The model includes effects for treatment,country/region, prior alpha-blocker therapy,baseline ED severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered bl value (defined as the bl value for a participant -the overall bl mean value),placebo lead-in total IPSS change(change from Visit 2 at Visit 3),centered bl-by-treatment and treatment-by-country/region interactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Patient Global Impression of Improvement (PGI-I) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>PGI-I measures a participant's perception of improvement at the time of assessment compared with the start of treatment. Score ranges from 1 (very much better) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinician Global Impression of Improvement (CGI-I) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>CGI-I measures clinician's perception of participant improvement at the time of assessment (compared with the start of treatment) with scores ranging from 1 (very much better) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IIEF Overall Satisfaction (OS) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF-OS is the sum of Questions 13 and 14. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each question, with a total subscore ranging from 2 to 10;higher scores represent better erectile function. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction,centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IIEF Intercourse Satisfaction at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF-IS is the sum of Questions 6,7 and 8 of the IIEF. Scores range from 0(low/no satisfaction) to 5(high satisfaction) for each question, with the total possible score for the 3 questions ranging from 0 to 15.Higher scores were indicative of an increase in intercourse satisfaction. Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction,centered baseline value(defined as the baseline value for a participant- the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IIEF Orgasmic Function at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF orgasmic function is the sum of Q9 and Q10 of the IIEF. Scores ranged from 0 (no stimulation) to 5 (almost always) for each question, with the total possible score for the 2 questions ranging from 0 to 10. Higher scores were indicative of better orgasmic function. Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IIEF Sexual Desire at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF sexual desire is the sum of Q11 and Q12. Scores ranged from 1 (low/almost never) to 5 (very high/almost always) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Higher scores were indicative of increased sexual desire. Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IIEF Subscores at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>IIEF Question 3 asks how often a participant was able to penetrate his partner over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). IIEF Question 4 asks whether/how often a participant was able to maintain an erection after penetration over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total IPSS at Week 4 and Week 8</measure>
    <time_frame>Baseline, Week 4; Baseline, Week 8</time_frame>
    <description>IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question is scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline ED severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IIEF EF at Week 4 and Week 8</measure>
    <time_frame>Baseline, Week 4; Baseline, Week 8</time_frame>
    <description>IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 were scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 was scored 1 (very low confidence) to 5 (very high confidence) with a total score ranging from 1 to 30. Higher scores represent better erectile function. LS mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Yes Responses to Question 2 of the SEP Questionnaire at Week 4 and Week 8</measure>
    <time_frame>Baseline, Week 4; Baseline, Week 8</time_frame>
    <description>Participant-assessed diary assesses the mean change from baseline in the percentage of &quot;yes&quot; responses to SEP Q2, &quot;Were you able to insert your penis into your partner's vagina?&quot;. The SEP Q2 score is determined as the percentage of &quot;yes&quot; responses to SEP Q2 out of all sexual attempts recorded during the time period. Change was defined as the percentage of &quot;yes&quot; responses at endpoint minus the percentage of &quot;yes&quot; responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p &gt;= 0.10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 4 and Week 8</measure>
    <time_frame>Baseline, Week 4; Baseline, Week 8</time_frame>
    <description>Participant-assessed diary assesses the mean change from baseline in the percentage of &quot;yes&quot; responses to SEP Q3, &quot;Did your erection last long enough for you to have successful intercourse?&quot;. The SEP Q3 score is determined as the percentage of &quot;yes&quot; responses to SEP Q3 out of all sexual attempts recorded during the time period. Change was defined as the percentage of &quot;yes&quot; responses at endpoint minus percentage of &quot;yes&quot; responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p &gt;= 0.10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified International Prostate Symptom Score (mIPSS) at Week 2</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>The modified IPSS is the total IPSS collected at 2 weeks post-baseline.The total IPSS is obtained by combining the scores of the responses to component questions 1 through 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from ANCOVA. The model includes terms for treatment, country/region, prior alpha-blocker use and baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p &gt;= 0.10.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">909</enrollment>
  <condition>Benign Prostate Hyperplasia</condition>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg Tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2 mg Tamsulosin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg Tadalafil</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>5 mg Tadalafil</arm_group_label>
    <other_name>LY450190</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>5 mg Tadalafil</arm_group_label>
    <arm_group_label>0.2 mg Tamsulosin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.2 mg Tamsulosin</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>0.2 mg Tamsulosin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Present with a history of ED and signs and symptoms of BPH.

          -  Are sexually active with an adult female partner, and expect to remain sexually active
             with the same adult female partner for the duration of the study.

        Main Exclusion Criteria:

          -  Current treatment with nitrates.

          -  Prostate-specific antigen (PSA) greater than 10.0 nanogram (ng)/mL at 1st screening.

          -  PSA greater than or equal to 4.0 to less than or equal to 10.0 ng/mL at 1st screening
             if prostate malignancy has not been ruled out to the satisfaction of a urologist

          -  Suffering from other urinary disease like cancer, or infection

          -  Serious cardiovascular disease

          -  History of significant renal insufficiency
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changsha</city>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chengdu</city>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hefei</city>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nanjing</city>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Suzhou</city>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wenzhou</city>
        <zip>325035</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wu Han</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Xi'An</city>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <results_first_submitted>December 14, 2016</results_first_submitted>
  <results_first_submitted_qc>December 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 7, 2017</results_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
        </group>
        <group group_id="P2">
          <title>5 mg Tadalafil</title>
          <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
        </group>
        <group group_id="P3">
          <title>0.2 mg Tamsulosin</title>
          <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="361"/>
                <participants group_id="P2" count="363"/>
                <participants group_id="P3" count="185"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="361"/>
                <participants group_id="P2" count="362"/>
                <participants group_id="P3" count="185"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="337"/>
                <participants group_id="P2" count="346"/>
                <participants group_id="P3" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
        </group>
        <group group_id="B2">
          <title>5 mg Tadalafil</title>
          <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
        </group>
        <group group_id="B3">
          <title>0.2 mg Tamsulosin</title>
          <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="361"/>
            <count group_id="B2" value="363"/>
            <count group_id="B3" value="185"/>
            <count group_id="B4" value="909"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.8" spread="7.35"/>
                    <measurement group_id="B2" value="61.8" spread="7.27"/>
                    <measurement group_id="B3" value="61.9" spread="7.06"/>
                    <measurement group_id="B4" value="61.8" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="361"/>
                    <measurement group_id="B2" value="363"/>
                    <measurement group_id="B3" value="185"/>
                    <measurement group_id="B4" value="909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="279"/>
                    <measurement group_id="B2" value="277"/>
                    <measurement group_id="B3" value="143"/>
                    <measurement group_id="B4" value="699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12</title>
        <description>IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question was scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM).The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline Erectile dysfunction (ED) severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment.The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IPSS measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12</title>
          <description>IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question was scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM).The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline Erectile dysfunction (ED) severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment.The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IPSS measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.08" spread="0.402"/>
                    <measurement group_id="O2" value="-5.49" spread="0.395"/>
                    <measurement group_id="O3" value="-4.92" spread="0.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.25</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at Week 12</title>
        <description>IIEF is a 15 item self-reported questionnaire to assess overall erectile function and satisfaction during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0(low/no erectile function) to 5(high erectile function) and Question 15 is scored 1(very low confidence) to 5(very high confidence) with a total score ranging from 1 to 30.Higher scores represent better erectile function.LS mean of change from baseline to endpoint is from MMRM.The model includes effects for treatment,country/region,baseline lower urinary tract symptoms(LUTS) severity (moderate/severe),visit,treatment-by-visit interaction,centered baseline value(defined as the baseline value for a participant-the overall baseline mean value), placebo lead-in total IPSS change(change from Visit 2 at Visit 3),centered baseline-by-treatment and treatment-by-country/region interactions.The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who had at least one dose of the study drug, had a baseline and at least one post-baseline IIEF measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at Week 12</title>
          <description>IIEF is a 15 item self-reported questionnaire to assess overall erectile function and satisfaction during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0(low/no erectile function) to 5(high erectile function) and Question 15 is scored 1(very low confidence) to 5(very high confidence) with a total score ranging from 1 to 30.Higher scores represent better erectile function.LS mean of change from baseline to endpoint is from MMRM.The model includes effects for treatment,country/region,baseline lower urinary tract symptoms(LUTS) severity (moderate/severe),visit,treatment-by-visit interaction,centered baseline value(defined as the baseline value for a participant-the overall baseline mean value), placebo lead-in total IPSS change(change from Visit 2 at Visit 3),centered baseline-by-treatment and treatment-by-country/region interactions.The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
          <population>All randomized participants who had at least one dose of the study drug, had a baseline and at least one post-baseline IIEF measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.448"/>
                    <measurement group_id="O2" value="5.24" spread="0.439"/>
                    <measurement group_id="O3" value="2.64" spread="0.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Yes Responses to Question 2 of the Sexual Encounter Profile (SEP) Questionnaire at Week 12</title>
        <description>Participant-assessed diary assesses the mean change from baseline in the percentage of &quot;yes&quot; responses to SEP Q2, &quot;Were you able to insert your penis into your partner's vagina?&quot;. The SEP Q2 score was determined as the percentage of &quot;yes&quot; responses to SEP Q2 out of all sexual attempts recorded during the time period. Change is defined as the percentage of yes responses at endpoint minus the percentage of yes responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p &gt;= 0.10.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline SEP measurement. Last Observation Carried Forward (LOCF) was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Yes Responses to Question 2 of the Sexual Encounter Profile (SEP) Questionnaire at Week 12</title>
          <description>Participant-assessed diary assesses the mean change from baseline in the percentage of &quot;yes&quot; responses to SEP Q2, &quot;Were you able to insert your penis into your partner's vagina?&quot;. The SEP Q2 score was determined as the percentage of &quot;yes&quot; responses to SEP Q2 out of all sexual attempts recorded during the time period. Change is defined as the percentage of yes responses at endpoint minus the percentage of yes responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p &gt;= 0.10.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline SEP measurement. Last Observation Carried Forward (LOCF) was used to impute missing post-baseline values.</population>
          <units>percentage of &quot;yes&quot; responses</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.90" spread="2.618"/>
                    <measurement group_id="O2" value="23.87" spread="2.548"/>
                    <measurement group_id="O3" value="6.84" spread="3.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 12</title>
        <description>Participant-assessed diary assesses the mean change from baseline in the percentage of &quot;yes&quot; responses to SEP Q3, &quot;Did your erection last long enough for you to have successful intercourse?&quot;.The SEP Q3 score is determined as the percentage of &quot;yes&quot; responses to SEP Q3 out of all sexual attempts recorded during the time period. Change was defined as the percentage of &quot;yes&quot; responses at endpoint minus percentage of &quot;yes&quot; responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p &gt;= 0.10.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline SEP measurement. Last Observation Carried Forward (LOCF) was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 12</title>
          <description>Participant-assessed diary assesses the mean change from baseline in the percentage of &quot;yes&quot; responses to SEP Q3, &quot;Did your erection last long enough for you to have successful intercourse?&quot;.The SEP Q3 score is determined as the percentage of &quot;yes&quot; responses to SEP Q3 out of all sexual attempts recorded during the time period. Change was defined as the percentage of &quot;yes&quot; responses at endpoint minus percentage of &quot;yes&quot; responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p &gt;= 0.10.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline SEP measurement. Last Observation Carried Forward (LOCF) was used to impute missing post-baseline values.</population>
          <units>percentage of &quot;yes&quot; responses</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.96" spread="3.016"/>
                    <measurement group_id="O2" value="36.62" spread="2.935"/>
                    <measurement group_id="O3" value="17.42" spread="3.557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IPSS at Week 12</title>
        <description>IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question is scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM).The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline Erectile dysfunction (ED) severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IPSS measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IPSS at Week 12</title>
          <description>IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question is scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM).The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline Erectile dysfunction (ED) severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IPSS measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.08" spread="0.402"/>
                    <measurement group_id="O2" value="-5.49" spread="0.395"/>
                    <measurement group_id="O3" value="-4.92" spread="0.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.87</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Uroflowmetry Measures at Week 12</title>
        <description>Qmax is defined as the peak urine flow rate (measured in milliliters per second [mL/sec] using standard calibrated flowmeter).
At each visit, a uroflowmetry assessment was considered valid and the data were included only if the prevoid total bladder volume (assessed by ultrasound) was &gt;=150 to &lt;=550 milliliters (mL) and the voided volume (Vcomp) was &gt;=125 mL. Changes in Qmax from baseline to endpoint in the double-blind treatment period were analyzed using Type III sums of squares ANOVA on rank-transformed data with a term for treatment group.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline Uroflowmetry measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Uroflowmetry Measures at Week 12</title>
          <description>Qmax is defined as the peak urine flow rate (measured in milliliters per second [mL/sec] using standard calibrated flowmeter).
At each visit, a uroflowmetry assessment was considered valid and the data were included only if the prevoid total bladder volume (assessed by ultrasound) was &gt;=150 to &lt;=550 milliliters (mL) and the voided volume (Vcomp) was &gt;=125 mL. Changes in Qmax from baseline to endpoint in the double-blind treatment period were analyzed using Type III sums of squares ANOVA on rank-transformed data with a term for treatment group.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline Uroflowmetry measurement.</population>
          <units>Milliliters/seconds (mL/sec)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="313"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="5.46"/>
                    <measurement group_id="O2" value="1.9" spread="5.68"/>
                    <measurement group_id="O3" value="2.0" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postvoid Residual Volume (PVR) at Week 12</title>
        <description>The amount of urine remaining in the bladder after void completion.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline PVR measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postvoid Residual Volume (PVR) at Week 12</title>
          <description>The amount of urine remaining in the bladder after void completion.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline PVR measurement.</population>
          <units>milliliters (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="341"/>
                <count group_id="O2" value="351"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="47.86"/>
                    <measurement group_id="O2" value="-3.8" spread="49.02"/>
                    <measurement group_id="O3" value="-9.5" spread="44.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IPSS Storage (Irritative) Subscore at Week 12</title>
        <description>IPSS Storage (Irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores ranged from 0 (no irritative symptoms) to 5 (frequent irritative symptoms), with total subscore of the 3 questions for irritative subscore ranging from 0 to 15; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline ED severity (mild/moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IPSS measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IPSS Storage (Irritative) Subscore at Week 12</title>
          <description>IPSS Storage (Irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores ranged from 0 (no irritative symptoms) to 5 (frequent irritative symptoms), with total subscore of the 3 questions for irritative subscore ranging from 0 to 15; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline ED severity (mild/moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IPSS measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68" spread="0.176"/>
                    <measurement group_id="O2" value="-2.01" spread="0.173"/>
                    <measurement group_id="O3" value="-1.90" spread="0.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IPSS Voiding (Obstructive) Subscore at Week 12</title>
        <description>IPSS voiding (obstructive) subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores ranged from 0 (no obstructive symptoms) to 5 (frequent obstructive symptoms), with total subscore of the 4 questions of the obstructive score ranging from 0 to 20; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline ED severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IPSS measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IPSS Voiding (Obstructive) Subscore at Week 12</title>
          <description>IPSS voiding (obstructive) subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores ranged from 0 (no obstructive symptoms) to 5 (frequent obstructive symptoms), with total subscore of the 4 questions of the obstructive score ranging from 0 to 20; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline ED severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IPSS measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.42" spread="0.271"/>
                    <measurement group_id="O2" value="-3.49" spread="0.266"/>
                    <measurement group_id="O3" value="-3.07" spread="0.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IPSS Quality of Life (QoL) Index at Week 12</title>
        <description>IPSS QoL assess participant response to the following question:&quot;If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?&quot;. Response options are Delighted(0),Pleased(1);Mostly satisfied(2);mixed about equally satisfied and dissatisfied(3);Mostly dissatisfied(4);Unhappy(5);Terrible(6),with a total ranging from 0 to 6; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares(LS) mean of change from baseline(bl) to endpoint is from MMRM.The model includes effects for treatment,country/region, prior alpha-blocker therapy,baseline ED severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered bl value (defined as the bl value for a participant -the overall bl mean value),placebo lead-in total IPSS change(change from Visit 2 at Visit 3),centered bl-by-treatment and treatment-by-country/region interactions.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline QoL measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IPSS Quality of Life (QoL) Index at Week 12</title>
          <description>IPSS QoL assess participant response to the following question:&quot;If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?&quot;. Response options are Delighted(0),Pleased(1);Mostly satisfied(2);mixed about equally satisfied and dissatisfied(3);Mostly dissatisfied(4);Unhappy(5);Terrible(6),with a total ranging from 0 to 6; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares(LS) mean of change from baseline(bl) to endpoint is from MMRM.The model includes effects for treatment,country/region, prior alpha-blocker therapy,baseline ED severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered bl value (defined as the bl value for a participant -the overall bl mean value),placebo lead-in total IPSS change(change from Visit 2 at Visit 3),centered bl-by-treatment and treatment-by-country/region interactions.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline QoL measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="0.099"/>
                    <measurement group_id="O2" value="-0.98" spread="0.097"/>
                    <measurement group_id="O3" value="-1.00" spread="0.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Patient Global Impression of Improvement (PGI-I) at Week 12</title>
        <description>PGI-I measures a participant's perception of improvement at the time of assessment compared with the start of treatment. Score ranges from 1 (very much better) to 7 (very much worse).</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline PGI-I measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Patient Global Impression of Improvement (PGI-I) at Week 12</title>
          <description>PGI-I measures a participant's perception of improvement at the time of assessment compared with the start of treatment. Score ranges from 1 (very much better) to 7 (very much worse).</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline PGI-I measurement.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="342"/>
                <count group_id="O2" value="353"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Little Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Little Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="164"/>
                    <measurement group_id="O3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Much Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinician Global Impression of Improvement (CGI-I) at Week 12</title>
        <description>CGI-I measures clinician's perception of participant improvement at the time of assessment (compared with the start of treatment) with scores ranging from 1 (very much better) to 7 (very much worse).</description>
        <time_frame>Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug and had a baseline and at least one post-baseline CGI-I measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinician Global Impression of Improvement (CGI-I) at Week 12</title>
          <description>CGI-I measures clinician's perception of participant improvement at the time of assessment (compared with the start of treatment) with scores ranging from 1 (very much better) to 7 (very much worse).</description>
          <population>All randomized participants who received at least one dose of the study drug and had a baseline and at least one post-baseline CGI-I measurement.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
                <count group_id="O2" value="353"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Little Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Little Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="140"/>
                    <measurement group_id="O3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Much Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IIEF Overall Satisfaction (OS) at Week 12</title>
        <description>IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF-OS is the sum of Questions 13 and 14. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each question, with a total subscore ranging from 2 to 10;higher scores represent better erectile function. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction,centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IIEF measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IIEF Overall Satisfaction (OS) at Week 12</title>
          <description>IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF-OS is the sum of Questions 13 and 14. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each question, with a total subscore ranging from 2 to 10;higher scores represent better erectile function. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction,centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IIEF measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.120"/>
                    <measurement group_id="O2" value="1.54" spread="0.118"/>
                    <measurement group_id="O3" value="0.71" spread="0.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IIEF Intercourse Satisfaction at Week 12</title>
        <description>IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF-IS is the sum of Questions 6,7 and 8 of the IIEF. Scores range from 0(low/no satisfaction) to 5(high satisfaction) for each question, with the total possible score for the 3 questions ranging from 0 to 15.Higher scores were indicative of an increase in intercourse satisfaction. Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction,centered baseline value(defined as the baseline value for a participant- the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IIEF measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period. Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IIEF Intercourse Satisfaction at Week 12</title>
          <description>IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF-IS is the sum of Questions 6,7 and 8 of the IIEF. Scores range from 0(low/no satisfaction) to 5(high satisfaction) for each question, with the total possible score for the 3 questions ranging from 0 to 15.Higher scores were indicative of an increase in intercourse satisfaction. Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction,centered baseline value(defined as the baseline value for a participant- the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IIEF measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.183"/>
                    <measurement group_id="O2" value="1.08" spread="0.179"/>
                    <measurement group_id="O3" value="0.41" spread="0.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IIEF Orgasmic Function at Week 12</title>
        <description>IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF orgasmic function is the sum of Q9 and Q10 of the IIEF. Scores ranged from 0 (no stimulation) to 5 (almost always) for each question, with the total possible score for the 2 questions ranging from 0 to 10. Higher scores were indicative of better orgasmic function. Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IIEF measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IIEF Orgasmic Function at Week 12</title>
          <description>IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF orgasmic function is the sum of Q9 and Q10 of the IIEF. Scores ranged from 0 (no stimulation) to 5 (almost always) for each question, with the total possible score for the 2 questions ranging from 0 to 10. Higher scores were indicative of better orgasmic function. Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IIEF measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.169"/>
                    <measurement group_id="O2" value="1.31" spread="0.165"/>
                    <measurement group_id="O3" value="0.57" spread="0.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IIEF Sexual Desire at Week 12</title>
        <description>IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF sexual desire is the sum of Q11 and Q12. Scores ranged from 1 (low/almost never) to 5 (very high/almost always) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Higher scores were indicative of increased sexual desire. Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IIEF measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period. Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IIEF Sexual Desire at Week 12</title>
          <description>IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF sexual desire is the sum of Q11 and Q12. Scores ranged from 1 (low/almost never) to 5 (very high/almost always) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Higher scores were indicative of increased sexual desire. Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IIEF measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.114"/>
                    <measurement group_id="O2" value="1.12" spread="0.111"/>
                    <measurement group_id="O3" value="0.28" spread="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IIEF Subscores at Week 12</title>
        <description>IIEF Question 3 asks how often a participant was able to penetrate his partner over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). IIEF Question 4 asks whether/how often a participant was able to maintain an erection after penetration over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IIEF measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IIEF Subscores at Week 12</title>
          <description>IIEF Question 3 asks how often a participant was able to penetrate his partner over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). IIEF Question 4 asks whether/how often a participant was able to maintain an erection after penetration over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline IIEF measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IIEF Question 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.097"/>
                    <measurement group_id="O2" value="0.87" spread="0.095"/>
                    <measurement group_id="O3" value="0.39" spread="0.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIEF Question 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.093"/>
                    <measurement group_id="O2" value="0.87" spread="0.091"/>
                    <measurement group_id="O3" value="0.50" spread="0.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total IPSS at Week 4 and Week 8</title>
        <description>IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question is scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline ED severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
        <time_frame>Baseline, Week 4; Baseline, Week 8</time_frame>
        <population>All randomized participants who had at least one dose of the study, had a baseline and at least one post-baseline IPSS measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total IPSS at Week 4 and Week 8</title>
          <description>IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question is scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline ED severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
          <population>All randomized participants who had at least one dose of the study, had a baseline and at least one post-baseline IPSS measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.99" spread="0.365"/>
                    <measurement group_id="O2" value="-4.10" spread="0.359"/>
                    <measurement group_id="O3" value="-3.92" spread="0.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.50" spread="0.385"/>
                    <measurement group_id="O2" value="-4.85" spread="0.378"/>
                    <measurement group_id="O3" value="-4.44" spread="0.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IIEF EF at Week 4 and Week 8</title>
        <description>IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 were scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 was scored 1 (very low confidence) to 5 (very high confidence) with a total score ranging from 1 to 30. Higher scores represent better erectile function. LS mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
        <time_frame>Baseline, Week 4; Baseline, Week 8</time_frame>
        <population>All randomized participants who had at least one dose of the study, had a baseline and at least one post-baseline IIEF measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IIEF EF at Week 4 and Week 8</title>
          <description>IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 were scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 was scored 1 (very low confidence) to 5 (very high confidence) with a total score ranging from 1 to 30. Higher scores represent better erectile function. LS mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p &gt;= 0.10.</description>
          <population>All randomized participants who had at least one dose of the study, had a baseline and at least one post-baseline IIEF measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="0.412"/>
                    <measurement group_id="O2" value="4.50" spread="0.403"/>
                    <measurement group_id="O3" value="1.43" spread="0.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.423"/>
                    <measurement group_id="O2" value="4.77" spread="0.414"/>
                    <measurement group_id="O3" value="2.19" spread="0.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Yes Responses to Question 2 of the SEP Questionnaire at Week 4 and Week 8</title>
        <description>Participant-assessed diary assesses the mean change from baseline in the percentage of &quot;yes&quot; responses to SEP Q2, &quot;Were you able to insert your penis into your partner's vagina?&quot;. The SEP Q2 score is determined as the percentage of &quot;yes&quot; responses to SEP Q2 out of all sexual attempts recorded during the time period. Change was defined as the percentage of &quot;yes&quot; responses at endpoint minus the percentage of &quot;yes&quot; responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p &gt;= 0.10.</description>
        <time_frame>Baseline, Week 4; Baseline, Week 8</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline SEP measurement. Last Observation Carried Forward (LOCF) was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period. Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Yes Responses to Question 2 of the SEP Questionnaire at Week 4 and Week 8</title>
          <description>Participant-assessed diary assesses the mean change from baseline in the percentage of &quot;yes&quot; responses to SEP Q2, &quot;Were you able to insert your penis into your partner's vagina?&quot;. The SEP Q2 score is determined as the percentage of &quot;yes&quot; responses to SEP Q2 out of all sexual attempts recorded during the time period. Change was defined as the percentage of &quot;yes&quot; responses at endpoint minus the percentage of &quot;yes&quot; responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p &gt;= 0.10.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline SEP measurement. Last Observation Carried Forward (LOCF) was used to impute missing post-baseline values.</population>
          <units>percentage of &quot;yes&quot; responses</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="328"/>
                    <count group_id="O2" value="344"/>
                    <count group_id="O3" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.43" spread="2.394"/>
                    <measurement group_id="O2" value="20.53" spread="2.325"/>
                    <measurement group_id="O3" value="6.21" spread="2.827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="350"/>
                    <count group_id="O3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.79" spread="2.510"/>
                    <measurement group_id="O2" value="23.22" spread="2.441"/>
                    <measurement group_id="O3" value="7.42" spread="2.950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 4 and Week 8</title>
        <description>Participant-assessed diary assesses the mean change from baseline in the percentage of &quot;yes&quot; responses to SEP Q3, &quot;Did your erection last long enough for you to have successful intercourse?&quot;. The SEP Q3 score is determined as the percentage of &quot;yes&quot; responses to SEP Q3 out of all sexual attempts recorded during the time period. Change was defined as the percentage of &quot;yes&quot; responses at endpoint minus percentage of &quot;yes&quot; responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p &gt;= 0.10.</description>
        <time_frame>Baseline, Week 4; Baseline, Week 8</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline SEP measurement. Last Observation Carried Forward (LOCF) was used to impute missing post-baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period. Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 4 and Week 8</title>
          <description>Participant-assessed diary assesses the mean change from baseline in the percentage of &quot;yes&quot; responses to SEP Q3, &quot;Did your erection last long enough for you to have successful intercourse?&quot;. The SEP Q3 score is determined as the percentage of &quot;yes&quot; responses to SEP Q3 out of all sexual attempts recorded during the time period. Change was defined as the percentage of &quot;yes&quot; responses at endpoint minus percentage of &quot;yes&quot; responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p &gt;= 0.10.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline SEP measurement. Last Observation Carried Forward (LOCF) was used to impute missing post-baseline values.</population>
          <units>percentage of &quot;yes&quot; responses</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="338"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="328"/>
                    <count group_id="O2" value="344"/>
                    <count group_id="O3" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.41" spread="2.701"/>
                    <measurement group_id="O2" value="23.38" spread="2.622"/>
                    <measurement group_id="O3" value="9.57" spread="3.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="350"/>
                    <count group_id="O3" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.08" spread="2.884"/>
                    <measurement group_id="O2" value="32.27" spread="2.805"/>
                    <measurement group_id="O3" value="14.98" spread="3.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified International Prostate Symptom Score (mIPSS) at Week 2</title>
        <description>The modified IPSS is the total IPSS collected at 2 weeks post-baseline.The total IPSS is obtained by combining the scores of the responses to component questions 1 through 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from ANCOVA. The model includes terms for treatment, country/region, prior alpha-blocker use and baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p &gt;= 0.10.</description>
        <time_frame>Baseline, Week 2</time_frame>
        <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline mIPSS measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>0.2 mg Tamsulosin</title>
            <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Modified International Prostate Symptom Score (mIPSS) at Week 2</title>
          <description>The modified IPSS is the total IPSS collected at 2 weeks post-baseline.The total IPSS is obtained by combining the scores of the responses to component questions 1 through 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from ANCOVA. The model includes terms for treatment, country/region, prior alpha-blocker use and baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p &gt;= 0.10.</description>
          <population>All randomized participants who received at least one dose of the study drug, had a baseline and at least one post-baseline mIPSS measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="358"/>
                <count group_id="O3" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.19" spread="0.342"/>
                    <measurement group_id="O2" value="-3.40" spread="0.336"/>
                    <measurement group_id="O3" value="-3.20" spread="0.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All randomized participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.</description>
        </group>
        <group group_id="E2">
          <title>5 mg Tadalafil</title>
          <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
        </group>
        <group group_id="E3">
          <title>0.2 mg Tamsulosin</title>
          <description>Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.
Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="362"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Melanosis coli</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="362"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Type v hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Refraction disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypermotility</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Intestinal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="361"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="362"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Blood urine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="361"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Enuresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatic calcification</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="361"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Pemphigus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="362"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="185"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

